These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30322471)

  • 21. Pharmacotherapy of hyperglycemia.
    Kulasa KM; Henry RR
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on DPP-4 inhibitors in the management of type 2 diabetes.
    Cahn A; Cernea S; Raz I
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):409-419. PubMed ID: 27809608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes].
    Álvarez-Guisasola F; Orozco-Beltrán D; Cebrián-Cuenca AM; Ruiz Quintero MA; Angullo Martínez E; Ávila Lachica L; Ortega Millán C; Caride Miana E; Navarro-Pérez J; Sagredo Perez J; Barrot de la Puente J; Cos Claramunt FX
    Aten Primaria; 2019; 51(7):442-451. PubMed ID: 31320123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN].
    Prieto MÁ; Comas Samper JM; Escobar Cervantes C; Gasull Molinera V
    Semergen; 2014; 40(5):261-73. PubMed ID: 24882393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gliptin-gliflozin combination for treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
    Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
    Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
    Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification.
    McGill JB
    Curr Diabetes Rev; 2012 Jul; 8(4):257-67. PubMed ID: 22515702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
    Yassin SA; Aroda VR
    Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of Cardiovascular Outcomes Trials in Type 2 Diabetes for Primary Care.
    Unger J
    J Fam Pract; 2018 Jun; 67(6 suppl):S35-S40. PubMed ID: 29912999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical review of sitagliptin: a DPP-4 inhibitor.
    Garg K; Tripathi CD; Kumar S
    J Assoc Physicians India; 2013 Sep; 61(9):645-9. PubMed ID: 24772702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Eur J Pharmacol; 2009 Mar; 605(1-3):170-6. PubMed ID: 19171131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
    Kaneko M; Narukawa M
    Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA; Marx N; Federici M
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
    Barnett AH
    Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.